Archives: 2021-03-05

PIER MARIA FORNASARI
2021-03-05

Can it work a single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster in a wide vaccination strategy ?

Vaccines to prevent COVID-19 infection are crucial for an effective global pandemic response. In The Lancet, Merryn Voysey and colleagues report the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomised controlled trials in the UK and Brazil and one double-blind study in South Africa. A subsequent report of

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

Transmission, reinfection and vaccine efficacy update for major SARS-CoV-2 variants B.1.1.7 (UK), B.1.3.5.1 (South Africa) and P1 (Brazil).

The topics was discussed in a recent webinar that the Massachusetts Consortium on Pathogen Readiness (MassCPR) held to “demystify” the new viral variants. Each consists of several mutations. Will the variants fuel “a novel stage of contagion, COVID 2.0?” opened George Daley, MD, PhD, dean of Harvard Medical School. “What has been unsettling is how many times mutations

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 B.1.1.7 (UK) variant is more transmissible with a 43%-90% higher reproduction number and could induce cases resurgences.

A variant of SARS-CoV-2 that emerged in southeast England in November 2020 is more transmissible than pre-existing variants, a new modeling study of Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, published on Science, finds. Further analyses suggest the variant B.1.1.7 will lead to large resurgences of COVID-19 cases.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

EMA starts rolling review of the Sputnik V COVID-19 vaccine

EMA’s human medicines committee (CHMP) has started a rolling review of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine1 developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology. The EU applicant for this medicine is R-Pharm Germany GmbH. The CHMP’s decision to start the rolling review is based on results from laboratory studies and clinical studies in adults.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 variant B.1.1.7 (so called UK) is susceptible to neutralizing antibodies elicited by wild type Spike vaccines

All current vaccines for COVID-19 utilize ancestral wild type SARS-CoV-2 Spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple Spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 501Y.V1 or 20I), contains eight

Read More

No Comments InCovid-19